Safety and Feasibility of Antiretroviral Preexposure Prophylaxis for Adolescent Men Who Have Sex With Men Aged 15 to 17 Years in the United States
Author(s) -
Sybil Hosek,
Raphael J. Landovitz,
Bill G. Kapogiannis,
George K. Siberry,
Bret J. Rudy,
Brandy Rutledge,
Nancy Liu,
D.R. Harris,
Kathleen Mulligan,
Gregory D. Zimet,
Kenneth H. Mayer,
Peter L. Anderson,
Jennifer J. Kiser,
Michelle Lally,
Jennifer Brothers,
Kelly Bojan,
Jim Rooney,
Craig M. Wilson
Publication year - 2017
Publication title -
jama pediatrics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.004
H-Index - 183
eISSN - 2168-6211
pISSN - 2168-6203
DOI - 10.1001/jamapediatrics.2017.2007
Subject(s) - medicine , pre exposure prophylaxis , men who have sex with men , emtricitabine , psychological intervention , population , human immunodeficiency virus (hiv) , young adult , intervention (counseling) , family medicine , gerontology , environmental health , viral load , antiretroviral therapy , psychiatry , syphilis
Adolescents represent a key population for implementing preexposure prophylaxis (PrEP) interventions worldwide, yet tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) for PrEP is only licensed for adults.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom